Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BioGaia AB Announces Results from Lactobacillus Reuteri Prodentis Study of Chronic Periodontitis Patients


Friday, 16 Aug 2013 07:30am EDT 

BioGaia AB announced that a double-blind, placebo-controlled study of chronic periodontitis patients showed that treatment with Lactobacillus reuteri Prodentis as an adjunct to standard treatment improved efficacy by 53%. The aim of the study was to evaluate the effects of Lactobacillus reuteri Prodentis as an adjunct to scaling and root planing, which is the standard treatment, in chronic periodontitis patients. By the end of the 12 week long study 53% fewer sites (surfaces on a teeth) in patients with deep dental pockets and supplemented by Lactobacillus reuteri Prodentis was in need for surgery, compared to the placebo group (p < 0.019). A site was considered as in need for surgery if the pocket depth was ≥6 mm or ≥5 mm and bleeding. After the intervention period it was also concluded that 67% of the patients in the placebo group fell into the high-risk category for disease progression, while the corresponding figure for patients supplemented by Lactobacillus reuteri Prodentis was only 27% (p < 0.027). Among the patients with more serious problems there was significantly more pocket depth reduction and attachment gain (p < 0.05) in the group supplemented by Lactobacillus reuteri Prodentis compared to corresponding patients in the placebo group. The study included 30 patients. 

Related Company News

Company Quote

179.0
-2.5 -1.38%
19 Dec 2014